Somewhat Positive News Coverage Somewhat Unlikely to Affect Hologic (HOLX) Stock Price

Media stories about Hologic (NASDAQ:HOLX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a news impact score of 0.08 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.4970449249972 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Several analysts have weighed in on the company. ValuEngine cut Hologic from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. BTIG Research reaffirmed a “buy” rating and issued a $44.00 price target on shares of Hologic in a report on Sunday, May 6th. BidaskClub raised Hologic from a “sell” rating to a “hold” rating in a report on Friday, April 27th. TheStreet cut Hologic from a “b-” rating to a “c-” rating in a report on Wednesday, May 2nd. Finally, Canaccord Genuity cut Hologic from a “buy” rating to a “hold” rating and lowered their price target for the company from $48.00 to $39.00 in a report on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. Hologic has a consensus rating of “Hold” and a consensus price target of $44.87.

Shares of NASDAQ HOLX traded up $0.04 during trading hours on Monday, reaching $38.30. 2,119,700 shares of the stock traded hands, compared to its average volume of 2,653,168. The stock has a market cap of $10.45 billion, a price-to-earnings ratio of 18.87, a P/E/G ratio of 1.80 and a beta of 0.87. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 1.13. Hologic has a 52-week low of $37.99 and a 52-week high of $38.33.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. The company had revenue of $789.30 million for the quarter, compared to analysts’ expectations of $781.23 million. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. Hologic’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.50 EPS. analysts forecast that Hologic will post 2.24 EPS for the current fiscal year.

In related news, Director Charles J. Dockendorff purchased 13,000 shares of Hologic stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average cost of $38.80 per share, for a total transaction of $504,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of the firm’s stock in a transaction that occurred on Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total value of $487,840.00. Following the transaction, the vice president now owns 13,825 shares in the company, valued at $553,000. The disclosure for this sale can be found here. Company insiders own 0.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with's FREE daily email newsletter.

Leave a Reply